MOSCOW, October 31, 2013 /PRNewswire/ --
Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced that Russia's International Biotechnology Center (IBC) Generium, has signed an agreement to grant access to ScienceDirect and Embase for its scientists.
Access to ScienceDirect, Elsevier's full-text platform for scientific, technical and medical research literature and Embase, the most comprehensive international database for biomedical researchers, supports the company's strategy to maintain its leading position in Russia in generic drug development and innovate in biotechnological therapies.
Established in 2011, Generium has a unique and extensive portfolio of innovative drugs and biotechnological therapies. Generium's aim is to innovate in biotechnological therapies against diseases such as oncology as well as cardio-vascular, neurodegenerative and autoimmune disorders. The center's research and development teams will benefit greatly from its newly acquired access to ScienceDirect and Embase, by providing them with peer-reviewed full-text research papers published in more than 2000 international journals, as well as timely access to biomedical information.
Dr. Andrei Petrov, Chief Scientific Officer of Generium, said, "We are delighted to reach this agreement with Elsevier providing our research and development teams with online access to an extensive stream of world-class scientific content which will substantially facilitate our own research on drug discovery and development. We consider both ScienceDirect and Embase as critical tools for strengthening our competitive position."
Igor Osipov, PhD, Elsevier Regional Director for Russia and Belarus said, "We are honored to work with Generium, marking our first collaboration within the corporate market for biotechnology in Russia. We are confident that access to ScienceDirect and Embase will help Generium to continuously innovate and expand their line of products."
The International Biotechnology Center "Generium", (LLC IBC Generium) is a private biotechnology research and development company founded in Russia in 2011. IBC Generium is a rapidly growing company with current portfolio of more than 30 innovative biotechnology-based medications and cell-based products. IBC Generium is highly focused on international collaboration approach and exchange of experience for discovery of innovative drugs.
ScienceDirect is home to almost one-quarter of the world's peer-reviewed full-text scientific, technical and medical content. Over 15 million researchers, health care professionals, teachers, students and information professionals around the globe rely on ScienceDirect as a trusted source of nearly 2,200 journals, almost 900 serials and close to 22,000 book titles. ScienceDirect supports research and education with interactive elements in articles such as audio, video, graphs, tables and images, and offers tools so users can easily set alerts. Content on ScienceDirect also features embedded links to external datasets, including earth and environmental science data from PANGAEA, abstract and indexing data from Scopus and chemical reactions data from Reaxys. With almost 12 million content pieces available-including pre-publication release of articles and open access content from Elsevier journals-ScienceDirect is a premier platform for discovering the world of research.
Embase from Elsevier Life Science Solutions is the most comprehensive international biomedical database for biomedical researchers. It enables you to track and retrieve precise information on drugs and diseases from pre-clinical studies to searches on critical toxicological information.
The database for biomedical research has over 25 million indexed records from 7,600 peer-reviewed journals, providing the confidence and tools required by Information managers, regulatory specialists, clinicians, medical librarians, educators and students to capture the most relevant and up-to-date biomedical research.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, helping research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions. The group employs more than 30,000 people, including more than 15,000 in North America. Reed Elsevier Group PLC is owned equally by two parent companies, Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RUK and ENL.